Display options
Cite
Baird A, Coimbra R, Dang X, et al. Up-regulation of the human-specific CHRFAM7A gene in inflammatory bowel disease. BBA Clin. 2016;5:66-71doi: 10.1016/j.bbacli.2015.12.003.
Baird, A., Coimbra, R., Dang, X., Eliceiri, B. P., & Costantini, T. W. (2016). Up-regulation of the human-specific CHRFAM7A gene in inflammatory bowel disease. BBA clinical, 566-71. https://doi.org/10.1016/j.bbacli.2015.12.003
Baird, Andrew, et al. "Up-regulation of the human-specific CHRFAM7A gene in inflammatory bowel disease." BBA clinical vol. 5 (2016): 66-71. doi: https://doi.org/10.1016/j.bbacli.2015.12.003
Baird A, Coimbra R, Dang X, Eliceiri BP, Costantini TW. Up-regulation of the human-specific CHRFAM7A gene in inflammatory bowel disease. BBA Clin. 2016 Jan 08;5:66-71. doi: 10.1016/j.bbacli.2015.12.003. eCollection 2016 Jun. PMID: 27051591; PMCID: PMC4802402.
Copy Download .nbib Format: NLM
Share it on

BBA Clin. 2016 Jan 08;5:66-71. doi: 10.1016/j.bbacli.2015.12.003. eCollection 2016 Jun.

Up-regulation of the human-specific CHRFAM7A gene in inflammatory bowel disease.

BBA clinical

Andrew Baird, Raul Coimbra, Xitong Dang, Brian P Eliceiri, Todd W Costantini

Affiliations

  1. Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery, Department of Surgery, University of California San Diego, La Jolla, CA, USA.
  2. Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery, Department of Surgery, University of California San Diego, La Jolla, CA, USA; The Key Laboratory of Medical Electrophysiology, Institute of Cardiovascular Research, Sichuan Medical University, Luzhou, China.

PMID: 27051591 PMCID: PMC4802402 DOI: 10.1016/j.bbacli.2015.12.003

Abstract

BACKGROUND: The α7-subunit of the α7-nicotinic acetylcholine receptor (α7-nAChR) is an obligatory intermediate for the anti-inflammatory effects of the vagus nerve. But in humans, there exists a second gene called CHRFAM7A that encodes a dominant negative α7-nAChR inhibitor. Here, we investigated whether their expression was altered in inflammatory bowel disease (IBD) and colon cancer.

METHODS: Quantitative RT-PCR measured gene expression of human α7-nAChR gene (CHRNA7), CHRFAM7A, TBC3D1, and actin in biopsies of normal large and small intestine, and compared to their expression in biopsies of ulcerative colitis, Crohn's disease, and colon cancer.

RESULTS: qRT-PCR showed that CHRFAM7A and CHRNA7 gene expression was significantly (p < .02) up-regulated in IBD (N = 64). Gene expression was unchanged in colon cancer. Further analyses revealed that there were differences in ulcerative colitis and Crohn's Disease. Colon biopsies of ulcerative colitis (N = 33) confirmed increased expression of CHRFAM7A and decreased in CHRNA7 expression (p < 0.001). Biopsies of Crohn's disease (N = 31), however, showed only small changes in CHRFAM7A expression (p < 0.04) and no change in CHRNA7. When segregated by tissue source, both CHRFAM7A up-regulation (p < 0.02) and CHRNA7 down-regulation (p < 0.001) were measured in colon, but not in small intestine.

CONCLUSION: The human-specific CHRFAM7A gene is up-regulated, and its target, CHRNA7, down-regulated, in IBD. Differences between ulcerative colitis and Crohn's disease tie to location of disease.

SIGNIFICANCE: The appearance of IBD in modern humans may be consequent to the emergence of CHRFAM7A, a human-specific α7-nAChR antagonist. CHRFAM7A could present a new, unrecognized target for development of IBD therapeutics.

References

  1. Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1167-72 - PubMed
  2. Acta Psychiatr Scand. 2006 Sep;114(3):211-5 - PubMed
  3. Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9935-40 - PubMed
  4. Am J Psychiatry. 2006 Oct;163(10):1832-4 - PubMed
  5. Genome Res. 2005 Dec;15(12):1746-58 - PubMed
  6. Genome Med. 2015 May 13;7(1):39 - PubMed
  7. Am J Med Genet B Neuropsychiatr Genet. 2006 Sep 5;141B(6):571-5 - PubMed
  8. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3507-12 - PubMed
  9. Drug Des Devel Ther. 2013 Nov 12;7:1341-57 - PubMed
  10. J Leukoc Biol. 2015 Feb;97(2):247-57 - PubMed
  11. Am J Med Genet A. 2015 Apr;167A(4):715-23 - PubMed
  12. Nature. 2003 Jan 23;421(6921):384-8 - PubMed
  13. Mol Med. 2015 Apr 03;21:323-36 - PubMed
  14. Genome Biol. 2004;5(7):R47 - PubMed
  15. PLoS Comput Biol. 2010 Mar 26;6(3):e1000734 - PubMed
  16. Neuropharmacology. 2015 Sep;96(Pt B):274-88 - PubMed
  17. Annu Rev Genet. 2013;47:307-33 - PubMed
  18. Curr Drug Targets. 2012 May;13(5):636-43 - PubMed
  19. Nat Rev Genet. 2011 Aug 31;12(10):692-702 - PubMed
  20. Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):74-9 - PubMed
  21. Inflamm Bowel Dis. 2014 Jun;20(6):967-77 - PubMed
  22. Am J Med Genet B Neuropsychiatr Genet. 2003 Nov 15;123B(1):39-49 - PubMed
  23. Int J Neuropsychopharmacol. 2009 Mar;12(2):267-73 - PubMed
  24. PLoS One. 2012;7(2):e31225 - PubMed
  25. Hum Mol Genet. 2002 May 15;11(11):1281-9 - PubMed
  26. Gene. 2003 Oct 30;318:169-75 - PubMed
  27. Hum Genomics. 2011 Jan;5(2):99-107 - PubMed
  28. Genome Biol. 2015 Oct 01;16:202 - PubMed
  29. PLoS One. 2013;8(2):e56818 - PubMed
  30. Am J Gastroenterol. 2011 Nov;106(11):2029-40 - PubMed
  31. Bioessays. 2012 Nov;34(11):982-91 - PubMed
  32. Biochem Pharmacol. 2011 Oct 15;82(8):904-14 - PubMed
  33. Nat Rev Genet. 2013 Sep;14(9):645-60 - PubMed
  34. PLoS One. 2014 May 12;9(5):e97425 - PubMed
  35. Shock. 2014 Jun;41(6):463-75 - PubMed
  36. Nucleic Acids Res. 2002 May 1;30(9):e36 - PubMed
  37. FASEB J. 2015 Jun;29(6):2292-302 - PubMed
  38. Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30 - PubMed
  39. Curr Pharm Des. 2014;20(7):1082-96 - PubMed
  40. Science. 2015 Mar 27;347(6229):1465-70 - PubMed
  41. J Biol Chem. 2011 Jan 7;286(1):594-606 - PubMed
  42. Neurosci Lett. 2004 Jan 23;355(1-2):69-72 - PubMed
  43. J Biol Chem. 2014 Sep 19;289(38):26451-63 - PubMed

Publication Types

Grant support